AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...